Table 1.
Demographic characteristics of the study participants.
| Discovery Cohort (mean ± SD) | Replication Cohort (mean ± SD) | p-values for differences between Discovery and Replication cohorts | |
|---|---|---|---|
| Sex, Male:Female | 667:686 | 673:503 | 7.96E-05 |
| Age, years ± SD | 47 ± 13.8 | 47 ± 10.7 | 0.97 |
| Weight, Kg ± SD | 88.5 ± 21.1 | 92.4 ± 17 | 3.62E-06 |
| Height, cm ± SD | 165 ± 9.6 | 166.5 ± 8.9 | 0.006 |
| BMI, Kg/m2 ± SD | 32.4 ± 7.4 | 31.2 ± 5.7 | 6.15E-06 |
| WC, cm ± SD | 102.2 ± 16.4 | 100.5 ± 12.1 | 0.003 |
| LDL, mmol/L ± SD | 3.1 ± 0.97 | 3.4 ± 0.9 | <2.2E-16 |
| HDL, mmol/L ± SD | 1.1 ± 0.4 | 1.1 ± 0.3 | 0.82 |
| TC, mmol/L ± SD | 4.9 ± 1.1 | 5.2 ± 1.0 | 7.77E-12 |
| TG, mmol/L ± SD | 1.7 ± 1.2 | 1.6 ± 1.0 | 0.002 |
| HbA1c, mmol/L ± SD | 7.1 ± 2.1 | 6.0 ± 1.4 | <2.2E-16 |
| FPG, mmol/L ± SD | 7.3 ± 3.6 | 5.9 ± 2.3 | <2.2E-16 |
| SBP, mmHg ± SD | 128 ± 17.5 | 129.1 ± 16.7 | 0.06 |
| DBP, mmHg ± SD | 77.9 ± 10.6 | 78.7 ± 11.1 | 0.035 |
| Proportion of the participants that are obese@ (BMI ≥ 30 Kg/m2) | 59.3% | 45.5% | 7.43E-05 |
| Proportion of the participants that are diabetic | 44.7% | 38.4% | 0.002 |
| Proportion of the participants that are hypertensive | 44.9% | 35.7% | 3.61E-06 |
| Proportion of the participants that consume lipid lowering medication | 9.8% | 0.3% | <2.2E-16 |
| Proportion of the participants that consume glucose lowering medication | 16.0% | 4.6% | <2.2E-16 |
| Proportion of the participants that consume blood pressure medication | 11.9% | 7.2% | 0.0 |
Abbreviations: WC, waist circumference; TC, total cholesterol; HbA1c, glycated hemoglobin; FPG, fasting plasma glucose; SBP, systolic blood pressure; DBP, diastolic blood pressure; SD, standard deviation.
@The distribution of the participants onto normal weight (BMI 20 to <25): overweight (BMI 25 to <30): obese (BMI 30 to <40): morbid obese (BMI ≥ = 40) = 222:328:597:206 in the discovery cohort; and 93:442:559:82 in the replication cohort.